Ademetionine

立即咨询

Ademetionine

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

29908-03-0

包装与价格：

包装	价格(元)
50mg	电议
100mg	电议
500mg	电议

产品介绍

化学性质

Storage	Store at -20°C
M.Wt	398.44
Cas No.	29908-03-0
Formula	C₁₅H₂₂N₆O₅S
Solubility	insoluble in EtOH; ≥108 mg/mL in H2O; ≥110.8 mg/mL in DMSO
Chemical Name	(2S)-2-amino-4-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(methyl)sulfonio)butanoate
Canonical SMILES	C[S+](C[C@](O1)([H])[C@](O)([H])[C@](O)([H])[C@]1([H])N2C=NC(C2=NC=N3)=C3N)CC[C@@](N)([H])C([O-])=O
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Ademetionine (S-adenosylmethionine; SAMe) is a naturally occurring metabolite present in all cells and biological fluids, and acts as a methyl donor in a variety of methylation reactions involving proteins, phospholipids, catecholamines and DNA. Ademetionine exhibits antidepressant activity associated with increases in brain monoamine neurotransmitters and improvement in muscarinic and β-adrenergic receptor functions. In addition, preliminary studies imply that ademetionine exhibits therapeutic potential in the treatment of other central nervous system disorders including dementia, acquired immune deficiency syndrome-associated myelopathy, as well as brain ischemia.

Reference:

1. Bottiglieri T. Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders. Expert Opinion on Investigational Drugs, 1997, 6(4): 417-426.

试验操作

Animal experiment:[1]
Animal models	Mice and rats
Dosage form	12.5, 25, 50, 100 and 200 mg/kg Subcutaneous injection
Applications	Ademetionine dose-dependently decreased immobility time in the forced swimming test in mice and rats, and the effect could be antagonized by haloperiodol.
Note	The technical data provided above is for reference only.
	References: 1. Bottiglieri T. Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders. Expert Opinion on Investigational Drugs, 1997, 6(4): 417-426.